WO2000023094A3 - Inhibition de l'activation et du recrutement des plaquettes - Google Patents

Inhibition de l'activation et du recrutement des plaquettes Download PDF

Info

Publication number
WO2000023094A3
WO2000023094A3 PCT/US1999/023641 US9923641W WO0023094A3 WO 2000023094 A3 WO2000023094 A3 WO 2000023094A3 US 9923641 W US9923641 W US 9923641W WO 0023094 A3 WO0023094 A3 WO 0023094A3
Authority
WO
WIPO (PCT)
Prior art keywords
recruitment
methods
platelet activation
inhibiting platelet
soluble
Prior art date
Application number
PCT/US1999/023641
Other languages
English (en)
Other versions
WO2000023094A2 (fr
Inventor
Charles R Maliszewski
Richard B Gayle Iii
Aaron J Marcus
Original Assignee
Immunex Corp
Cornell Res Foundation Inc
Charles R Maliszewski
Richard B Gayle Iii
Aaron J Marcus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp, Cornell Res Foundation Inc, Charles R Maliszewski, Richard B Gayle Iii, Aaron J Marcus filed Critical Immunex Corp
Priority to US09/807,660 priority Critical patent/US7264809B1/en
Priority to AU64256/99A priority patent/AU6425699A/en
Publication of WO2000023094A2 publication Critical patent/WO2000023094A2/fr
Publication of WO2000023094A3 publication Critical patent/WO2000023094A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01005—Apyrase (3.6.1.5), i.e. ATP diphosphohydrolase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

L'invention concerne des polypeptides CD39 solubles et des compositions contenant ces derniers, ainsi que des procédés permettant d'inhiber l'activation et le recrutement des plaquettes chez un mammifère par l'administration d'un polypeptide CD39 soluble.
PCT/US1999/023641 1998-10-16 1999-10-13 Inhibition de l'activation et du recrutement des plaquettes WO2000023094A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US09/807,660 US7264809B1 (en) 1998-10-16 1999-10-13 Methods of inhibiting platelet activation and recruitment
AU64256/99A AU6425699A (en) 1998-10-16 1999-10-13 Methods of inhibiting platelet activation and recruitment

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US10458598P 1998-10-16 1998-10-16
US60/104,585 1998-10-16
US10746698P 1998-11-06 1998-11-06
US60/107,466 1998-11-06
US14901099P 1999-08-13 1999-08-13
US60/149,010 1999-08-13

Publications (2)

Publication Number Publication Date
WO2000023094A2 WO2000023094A2 (fr) 2000-04-27
WO2000023094A3 true WO2000023094A3 (fr) 2000-07-27

Family

ID=27379766

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1999/022955 WO2000023459A1 (fr) 1998-10-16 1999-10-13 Inhibiteurs de l'activation et du recrutement plaquettaires
PCT/US1999/023641 WO2000023094A2 (fr) 1998-10-16 1999-10-13 Inhibition de l'activation et du recrutement des plaquettes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US1999/022955 WO2000023459A1 (fr) 1998-10-16 1999-10-13 Inhibiteurs de l'activation et du recrutement plaquettaires

Country Status (7)

Country Link
EP (1) EP1123306A4 (fr)
JP (1) JP2002527096A (fr)
AU (2) AU6425699A (fr)
CA (1) CA2345382A1 (fr)
IL (1) IL142539A0 (fr)
NZ (1) NZ511488A (fr)
WO (2) WO2000023459A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7264809B1 (en) 1998-10-16 2007-09-04 Immunex Corporation Methods of inhibiting platelet activation and recruitment
AU2507700A (en) 1999-01-15 2000-08-01 Biogen, Inc. Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
GB9914326D0 (en) * 1999-06-18 1999-08-18 Rademacher Group Limited Materials and methods relating to the diagnosis and treatment of pre-eclampsia
EP1305342A2 (fr) * 2000-07-24 2003-05-02 Attenuon, LLC Polypeptides du domaine d5 humain de production de kininees et ses utilisations
MY128992A (en) * 2000-08-25 2007-03-30 Merck Patent Gmbh Saratin for inhibiting platelet adhesion to collagen
AU2002361763A1 (en) * 2001-12-17 2003-06-30 Beth Israel Deaconess Medical Center Method of reducing angiogenesis
ES2500918T3 (es) 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Proteínas de fusión de albúmina e interferón beta
EP1585817B1 (fr) 2002-02-20 2009-09-02 The General Hospital Corporation Conjugues contenant un polymere biodegradable, et leurs utilisations
US20060240004A1 (en) 2002-04-09 2006-10-26 Linda Burkly Methods for treating tweak-related conditions
CA2496795C (fr) 2002-08-28 2014-06-03 Paul B. Burton Compositions et procedes de traitement de maladies cardio-vasculaires
WO2004024906A1 (fr) 2002-09-13 2004-03-25 UNIVERSITé LAVAL Nucleoside triphosphate diphosphohydrolase et utilisations de celle-ci
US7247300B1 (en) 2002-11-07 2007-07-24 Apt Therapeutics, Inc. Therapeutic use of soluble CD39L3
EP1733045A4 (fr) 2004-02-27 2008-08-13 Apt Therapeutics Inc Conception et utilisation therapeutique d'apyrases ameliorees par adpase
WO2006089095A2 (fr) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Traitement de troubles neurologiques
EP1885388B1 (fr) 2005-05-10 2013-09-11 Biogen Idec MA Inc. Traitement et evaluation des troubles inflammatoires
NZ564092A (en) * 2005-05-27 2010-05-28 Biogen Idec Inc TWEAK binding antibodies
WO2006138219A2 (fr) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Procedes d'evaluation de patients
DE102006046410A1 (de) * 2006-09-20 2008-03-27 Eberhard-Karls-Universität Tübingen Universitätsklinikum Arzneimittel zur Prophylaxe oder Behandlung oder Diagnostik von ischämischen Krankheiten
GB201522541D0 (en) * 2015-12-21 2016-02-03 Inst Research In Biomedicine Compositions
CN108203457B (zh) * 2016-12-20 2022-09-06 山西医科大学 一种靶向抑制血小板聚集的抗栓小肽ωKWR
EP3424957A1 (fr) * 2017-07-03 2019-01-09 advanceCOR GmbH Protéine de fusion
UY38299A (es) 2018-07-18 2020-02-28 Novartis Ag Apirasas solubilizadas, métodos y usos
WO2024023746A1 (fr) * 2022-07-29 2024-02-01 Novartis Ag Production améliorée de variants de cd39

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0416673A1 (fr) * 1989-08-03 1991-03-13 Centro De Ingenieria Genetica Y Biotecnologia Expression de protéines étrangères à partir de protéines de fusion exprimées par E. coli, leurs utilisations, vecteurs d'expression et souches recombinantes
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
WO1996030532A1 (fr) * 1995-03-24 1996-10-03 Novartis Ag Therapie genique utile lors de transplantations et contre les inflammations ou les thromboses
WO1996032471A2 (fr) * 1995-04-10 1996-10-17 Universite De Sherbrooke Atp-diphosphohydrolases, procedes de purification et de production de ces dernieres par recombinaison genetique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506126A (en) * 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0416673A1 (fr) * 1989-08-03 1991-03-13 Centro De Ingenieria Genetica Y Biotecnologia Expression de protéines étrangères à partir de protéines de fusion exprimées par E. coli, leurs utilisations, vecteurs d'expression et souches recombinantes
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
WO1996030532A1 (fr) * 1995-03-24 1996-10-03 Novartis Ag Therapie genique utile lors de transplantations et contre les inflammations ou les thromboses
WO1996032471A2 (fr) * 1995-04-10 1996-10-17 Universite De Sherbrooke Atp-diphosphohydrolases, procedes de purification et de production de ces dernieres par recombinaison genetique

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHADWICK B P ET AL: "The CD39-like gene family: identification of three new human members (CD39L2, CD39L3, and CD39L4), their murine homologues, and a member of the gene family from Drosophila melanogaster", GENOMICS,US,ACADEMIC PRESS, SAN DIEGO, vol. 50, no. 3, 15 June 1998 (1998-06-15), pages 357 - 367, XP002117226, ISSN: 0888-7543 *
CULLEN B. R.: "expression of a cloned human interleukin-2 cdna is emhanced by the substitution of a heterologous mrna leader region", DNA, vol. 7, no. 9, 1988, pages 645 - 650, XP000892169 *
GAYLE RICHARD B III ET AL: "Inhibition of platelet function by recombinant soluble ecto-ADPase/CD39.", JOURNAL OF CLINICAL INVESTIGATION MAY 1, 1998, vol. 101, no. 9, 1 May 1998 (1998-05-01), pages 1851 - 1859, XP002136365, ISSN: 0021-9738 *
MARCUS AARON J ET AL: "The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39.", JOURNAL OF CLINICAL INVESTIGATION 1997, vol. 99, no. 6, 1997, pages 1351 - 1360, XP002136366, ISSN: 0021-9738 *

Also Published As

Publication number Publication date
IL142539A0 (en) 2002-03-10
AU6425699A (en) 2000-05-08
EP1123306A1 (fr) 2001-08-16
NZ511488A (en) 2003-10-31
AU772460B2 (en) 2004-04-29
CA2345382A1 (fr) 2000-04-27
EP1123306A4 (fr) 2002-07-03
JP2002527096A (ja) 2002-08-27
AU6411599A (en) 2000-05-08
WO2000023459A1 (fr) 2000-04-27
WO2000023094A2 (fr) 2000-04-27

Similar Documents

Publication Publication Date Title
WO2000023094A3 (fr) Inhibition de l'activation et du recrutement des plaquettes
GR1002893B (el) Φαρμακευτικες συνθεσεις με εντερικη επικαλυψη
WO2003079972A3 (fr) Systemes de distribution d'agents actifs et methodes de protection et d'administration d'agents actifs
WO2004058837A3 (fr) Copolymere ampholytique et son utilisation
ZA981132B (en) Methods, compositions and articles for reducing or preventing the effects of inflammation.
WO2002062377A3 (fr) Utilisation combinee de polypeptides de facteur vii et des polypeptides de facteur vii
HUP0002381A3 (en) Apolipoprotein a-1 agonist peptide derivatives, complexes thereof and pharmaceutical compositions comprising their
AU2792799A (en) Novel peptide copolymer compositions
IL142531A0 (en) Cyclic peptide compound, processes for the preparation thereof and pharmaceutical compositions containing the same
AUPP051497A0 (en) Antimicrobial peptides
WO2000013703A3 (fr) Methodes de traitement de l'hypertension et compositions utiles a cet effet
WO1999043310A3 (fr) Antagonistes et agonistes de 20-hete
IL126714A (en) Use of cells, organs or components thereof for the preparation of a pharmaceutical composition for establishing selective immune downregulation
EP0999219A3 (fr) Peptides se liant á l'heparine
ZA200110150B (en) Streptogramin derivatives, preparation and compositions containing them.
EP1097646A3 (fr) Préparation à base de poudre de lait modifié
WO1999021574A3 (fr) Amelioration d'activite morphogene
AU4373197A (en) Recombinant single chain antibodies directed against the gp54 cancer marker, composition comprising same and use thereof
EP0921805A4 (fr) Peptides reconnus par des lymphocytes cytotoxiques specifiques du melanome restreints par a1, a2 et a3, leurs utilisations
EP0784979A3 (fr) Formulations contenant une protéine de l'obésité
ZA9710435B (en) Stabilized pharmaceutical compositions based on quinupristine and on dalfopristine and their preparation.
EP0784982A3 (fr) Préparation des protéines contre l'obésité
AU3113600A (en) Anticancer agents based on prevention of protein prenylation
WO2000017366A3 (fr) Composition pharmaceutique de pretraitement d'un patient necessitant un medicament ou un promedicament
IL146812A0 (en) Streptogramin derivatives, production thereof and compositions containing the same

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 1999 64256

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09807660

Country of ref document: US

122 Ep: pct application non-entry in european phase